Tg Therapeutics Stock Analysis

TGTX Stock Analysis Notes

About 63.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. TG Therapeutics had 100:5625 split on the 30th of April 2012. TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. Tg Therapeuticscmn operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people. To find out more about TG Therapeutics contact Michael Esq at 212 554 4484 or learn more at https://www.tgtherapeutics.com.

TG Therapeutics Investment Alerts

TG Therapeutics Upcoming and Recent Events

TGTX Largest EPS Surprises

View All Earnings Estimates

TG Therapeutics Environmental, Social, and Governance (ESG) Scores

TG Therapeutics Thematic Classifications

TGTX Stock Institutional Investors

Note, although TG Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

TGTX Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.75 B.

TGTX Profitablity

The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.

Management Efficiency

TG Therapeutics has return on total asset (ROA) of 0.0578 % which means that it generated a profit of $0.0578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1222 %, meaning that it created $0.1222 on every $100 dollars invested by stockholders. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2025, whereas Return On Capital Employed is likely to drop 0.07 in 2025. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 594.7 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 7.6 M in 2025.

Technical Drivers

As of the 23rd of March, TG Therapeutics owns the Risk Adjusted Performance of 0.123, downside deviation of 3.08, and Mean Deviation of 2.93. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TG Therapeutics, as well as the relationship between them.

TG Therapeutics Price Movement Analysis

TG Therapeutics Insider Trading Activities

TG Therapeutics Outstanding Bonds

TG Therapeutics Predictive Daily Indicators

TG Therapeutics Corporate Filings

TG Therapeutics Forecast Models

TG Therapeutics' time-series forecasting models are one of many TG Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TG Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how TG Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling TGTX shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as TG Therapeutics. By using and applying TGTX Stock analysis, traders can create a robust methodology for identifying TGTX entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. TGTX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. TGTX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

TG Therapeutics stock analysis indicators help investors evaluate how TG Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading TG Therapeutics shares will generate the highest return on investment. By understating and applying TG Therapeutics stock analysis, traders can identify TG Therapeutics position entry and exit signals to maximize returns.

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.